Navigation Links
WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
Date:2/23/2010

SHANGHAI, China, Feb. 23 /PRNewswire-Asia/ -- WuXi PharmaTech ( WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

WuXi produces solid oral dosage forms-tablets and capsules-for use in clinical trials in its Shanghai c-GMP manufacturing facility. In its analytical testing facility, WuXi develops and validates methods of analyzing APIs and formulated drug products for properties such as potency, purity and solubility. The company also offers compound stability tests and tests necessary for the release of APIs and drug products for clinical trial use. WuXi also delivers services related to regulatory compliance with chemistry, manufacturing and controls, or CMC, requirements, including creation of a readiness testing package for an Investigational New Drug filing and development of a full CMC package.

"We are very pleased to have passed this EMEA audit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "The agency's inspection outcome confirms that these two facilities meet international GMP standards.

"We pride ourselves on the quality of our facilities, processes, and people," Dr. Li continued. "Research manufacturing and analytical testing are important functions in a continuum of integrated drug discovery and development services that WuXi provides to our global customers. Our mission is to help our global customers to improve the success of discovery and shorten the time of development of new medical products."

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Stephanie Liu
     Associate Director of Corporate Communications Department
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

     Web:   http://www.wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Back to top

RELATED LINKS
http://www.wuxiapptec.com

'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
2. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
3. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
4. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
5. Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals
6. Lilly Surpasses United Way 2009 Campaign Goal
7. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
8. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
9. Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day
10. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
11. Vision Inspection Systems Specialist Acquire Automation Expands Employee Base, Launches New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 ... H1 2016" market research report with comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... The Global Wellness Summit (GWS), an annual conference for ... wellness, travel, spa and beauty in Europe. The organization asked its partner experts in ... and researchers - to forecast where wellness is headed in Europe. Predictions range from ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its stance on traditional ... to keep their households lice free. , According to a May 26 article ... keep kids in the classroom despite the fact that they may be harboring an ...
(Date:5/29/2016)... ... ... Whole Health Supply is happy to announce the favorable reception of its ... new style of nail clipper has a wider jaw opening that is useful for ... actual handle is 2.5mm thick to accommodate the cutting force. This is the maximum ...
Breaking Medicine News(10 mins):